Anti-Cathepsin B Market Is Expected to Reach US$ 208.19 Million at a 2.8% CAGR By 2027 – Coherent Market Insights

Cathepsin B is a cysteine protease that is primarily found in the lysosomes of normal cells, but it is secreted or associated with the plasma membrane of many transformed cells. It is found in all animals and other organisms, and performs a key role in cellular protein turnover. The cathepsin family includes serine proteases, aspartic proteases, and cysteine proteases. The aspartyl protease class is composed of cathepsins D and E. The cysteine protease class comprises of cathepsins B, L, H, K, S, and O. Currently, there are no approved cathepsin inhibitors in the market, however research is underway for the development of novel cathepsin inhibitors for treatment of various conditions such as cancer, traumatic brain injury, Ebola infection, and others.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4169

Anti-cathepsin B is also used in screening kits for diagnostic purposes. Antibodies of cathepsin B are used that recognizes an epitope on the heavy chain of mature Cathepsin B and therefore detects both mature and pro Cathepsin B. The anti-cathepsin B antibodies are used for ELISA, western blotting, flow cytometry and other screening purposes. It can be used to screen diseases like demyelination, emphysema, rheumatoid arthritis, and neoplastic infiltration.

Anti-cathepsin B Market – Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic has significantly augmented demand of anti-cathepsin B market. The spread of coronavirus is positively impacted the anti-cathepsin B market as the antibodies are expected to potential cure for COVID-19. For instance, according to data published in the Journal of Clinical Medicine Research on 5^th May 2020, acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin II receptor in different tissues of the body, especially in the mouth cavity and the tongue and the skin. Therefore, it needs the serine protease, transmembrane serine protease 2 (TMPRSS2) for cell entry. Cathepsin L/B (CTSL/CTSB) plays an important role in a second pathway, the endosomal pathway. Hence, anti-cathepsin B treatment may provide potential solutions for coronavirus treatment.

The anti-cathepsin B market is estimated to be valued at US$ 166.52 million in 2020 and is expected to exhibit a CAGR of 2.8 % during the forecast period (2020-2027).

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4169

Figure 1: Anti-cathepsin B Market Share (%) Analysis, By Type, 2020

The Increasing Prevalence of Diseases Treated With Anti-Cathepsin B, and Research and Development Activities Are Expected To Drive Growth of the Anti-Cathepsin B Market

Anti-cathepsin B is expected to be useful for treating other conditions such as cancer, traumatic brain injury, Ebola infection, fertility problems, and others. Therefore, the increasing prevalence of such diseases is expected to boost the anti-cathepsin B market growth over the forecast period. For instance, according to the GLOBOCAN 2018 database, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. As per the same source, one in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease.

Furthermore, the anti-cathepsin B market is expected to witness significant growth in the near future owing to the increasing research and development activities. For instance, the report titled “Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate” published in Frontiers Neurology Journal in September 2015, showed supporting evidence for cathepsin B, a cysteine protease, as a potentially important drug target for traumatic brain injury (TBI). Cathepsin B expression is greatly up-regulated in TBI animal models, as well as in trauma patients.

Chemical inhibitors of cathepsin B are effective in improving deficits in TBI and related injuries including ischemia, cerebral bleeding, cerebral aneurysm, edema, pain, infection, rheumatoid arthritis, epilepsy, Huntington’s disease, multiple sclerosis, and Alzheimer’s disease. The inhibitor E64d is unique among cathepsin B inhibitors and is the only compound to have demonstrated oral efficacy in a TBI model and prior safe use in human and is an effective tool compound for preclinical testing and clinical compound development.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/anti-cathepsin-b-market-3419

Anti-cathepsin B Market – Regional Analysis

The North America anti-cathepsin B market is expected to hold a dominant position in the global cathepsin inhibitors market owing to the high prevalence of conditions such as cancer and traumatic brain injury which will increase demand for novel treatment approaches such as anti-cathepsin B in this region. For instance, according to data published by the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer will be diagnosed in the U.S. and around 609,640 people will die from the disease.

Furthermore, a wide range of anti-cathepsin B products offered by key players is expected to accelerate the growth of the anti-cathepsin B market in the near future. For instance, Merck KGaA a Germany-based pharmaceutical, chemical and life sciences products company offers various anti-cathepsin products under the Calbiochem brand. The Cathepsin B Inhibitor II controls the biological activity of Cathepsin B. This small molecule/inhibitor is primarily used for Protease Inhibitors Techniques. The company also offers diagnostic products such as Cathepsin B Inhibitor Screening Kit which is a simple assay for screening potential inhibitors of CTSB (cathepsin B).

Figure 2: Anti-cathepsin B Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Anti-cathepsin B Market – Competitive Landscape

Key players operating in the anti-cathepsin B market are Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc., and Abcam Plc

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837